Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | FOS | P01100 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | JUN | P05412 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12806458 | 0.83 | PTGS2 (0.48) | CYP1A2CYP2A6ALOX15ALOX12FOS | |
| SCHEMBL24838152 | 0.80 | ALDH1A1 (0.42) | — | |
| SCHEMBL29342033 | 0.79 | CYP1A2 (0.36) | TRPA1CYP1A2CYP2A6ALOX15AKR1C3 | |
| SCHEMBL23902046 | 0.79 | ALDH1A1 (0.44) | CYP1A2 | |
| SCHEMBL4610099 | 0.79 | TRPA1 (0.59) | TRPA1CYP1A2CYP2A6ALOX15ALOX12 | |
| SCHEMBL2465452 | 0.75 | TRPA1 (0.41) | TRPA1ALOX12 | |
| SCHEMBL29342034 | 0.74 | ALDH1A1 (0.59) | CYP1A2 | |
| SCHEMBL10435972 | 0.73 | GABRA1 (0.42) | TRPA1 | |
| SCHEMBL10348370 | 0.73 | HTR2A (0.44) | TRPA1 | |
| SCHEMBL16957488 | 0.73 | HTT (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251289-A1 | USE OF ALKANE SULFONIC ACID FOR PREPARING PHENOLIC ALCOHOL | ARKEMA FRANCE (FR) | 2016-09-01 | — | — | US | disclosed |
| US-6965056-B1 | Removal of salts in the manufacture of phenolic compound | SHELL OIL COMPANY (US) | 2005-11-15 | — | — | US | disclosed |
| US-6720461-B2 | ADDING WATER AND A DILUENT TO FORM A SEPARABLE CRUDE PHENOLIC BOTTOMS STREAM HAVING A COMBINED DENSITY LOWER THAN THE DENSITY OF THE BOTTOMS; SEPARATING OUT A HYDROCARBON PHASE AND A SALT-CONTAINING AQUEOUS PHASE; PHENOLS FROM PEROXIDES | SHELL OIL COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-20010000260-A1 | Removal of salts in the manufacture of phenolic compound | SHELL OIL COMPANY | 2001-04-12 | — | — | US | disclosed |
| EP-0028910-B1 | IMPROVED PROCESS FOR PRODUCING PHENOLIC COMPOUNDS FROM ARALKYL HYDROPEROXIDES | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1983-04-20 | — | — | EP | disclosed |
| US-4328377-A | ACID CLEAVAGE OF ARYL HYDROPEROXIDES | MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) | 1982-05-04 | — | — | US | disclosed |
| EP-0028910-A1 | Improved process for producing phenolic compounds from aralkyl hydroperoxides | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1981-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251289-A1 | USE OF ALKANE SULFONIC ACID FOR PREPARING PHENOLIC ALCOHOL | ADH1C, ADH1A, ADH5 | TRPA1 813/4885CYP1A2 186/4885CYP2A6 31/4885 |
| US-20010000260-A1 | Removal of salts in the manufacture of phenolic compound | SRMS, AGT, TYR | TRPA1 3643/4885CYP1A2 562/4885CYP2A6 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.